French AFU Cancer Committee Guidelines - Update 2026-2028: Prostate Cancer - Treatment of relapse and metastatic disease.
Researchers
Guillaume Ploussard, Charles Dariane, Romain Mathieu, Michaël Baboudjian, Eric Barret, Laurent Brureau, Gaëlle Fiard, Gaëlle Fromont, Jonathan Olivier, François Rozet, Arthur Peyrottes, Raphaële Renard-Penna, Paul Sargos, Stéphane Supiot, Léa Turpin, Guilhem Roubaud, Morgan Rouprêt
Abstract
The Cancer Committee of the French Association of Urology (CCAFU) proposes an update of the recommendations for the management of recurrent and/or metastatic prostate cancer (PCa). A systematic review of the literature from 2024 to 2026 was conducted by the CCAFU to examine the elements of therapeutic management of recurrent prostate cancer after local or metastatic treatment, evaluating the references and their level of evidence. Molecular imaging is the standard assessment for recurrence after local treatment. Its use should not delay early salvage therapy. Androgen deprivation therapy (ADT) is the cornerstone of treatment for metastatic prostate cancer (PCa). Intensification of ADT, combined with at least one androgen receptor pathway inhibitor (ARPI), is now a standard of care for metastatic PCa. Other agents may be added depending on tumor characteristics and patient eligibility. Radiation therapy of the primary tumor is standard for patients with low tumor volume or fewer than 5 metastases on conventional imaging. For patients with castration-resistant PCa (CRPC), PARP inhibitors and PSMA-guided internal radiotherapy are newer treatment options. The combination and sequencing of treatments depend on numerous factors (patient and disease characteristics, prior lines of therapy, genomic status, and molecular imaging). This update of the French recommendations should contribute to improving the management of patients with recurrent or metastatic prostate cancer.Source: PubMed (PMID: 43051704)View Original on PubMed